Novartis AG Company Profile (NYSE:NVS)

About Novartis AG

Novartis AG logoNovartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: NVS
  • CUSIP:
Key Metrics:
  • Previous Close: $75.54
  • 50 Day Moving Average: $78.84
  • 200 Day Moving Average: $79.04
  • 52-Week Range: $69.90 - $93.58
  • Trailing P/E Ratio: 26.97
  • Foreward P/E Ratio: 14.70
  • P/E Growth: 2.72
  • Market Cap: $179.88B
  • Outstanding Shares: 2,381,221,000
  • Beta: 0.57
  • Net Margins: 13.84%
  • Return on Equity: 15.33%
  • Return on Assets: 8.66%
  • Debt-to-Equity Ratio: 0.22%
  • Current Ratio: 0.90%
  • Quick Ratio: 0.65%
Additional Links:
Companies Related to Novartis AG:

Analyst Ratings

Consensus Ratings for Novartis AG (NYSE:NVS) (?)
Ratings Breakdown: 2 Sell Ratings, 9 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.13)
Consensus Price Target: $92.75 (22.78% upside)

Analysts' Ratings History for Novartis AG (NYSE:NVS)
DateFirmActionRatingPrice TargetDetails
10/16/2016Jefferies GroupReiterated RatingBuyView Rating Details
10/10/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00View Rating Details
8/25/2016ArgusReiterated RatingHoldView Rating Details
7/12/2016Bank of America Corp.Reiterated RatingHoldView Rating Details
5/24/2016Citigroup Inc.Reiterated RatingNeutralView Rating Details
5/2/2016Leerink SwannReiterated RatingHoldView Rating Details
4/22/2016Barclays PLCUpgradeUnderweight -> Equal WeightView Rating Details
4/14/2016Credit Suisse Group AGReiterated RatingHoldView Rating Details
4/12/2016Morgan StanleyDowngradeEqual Weight -> UnderweightView Rating Details
1/28/2016BNP ParibasDowngradeOutperform -> NeutralView Rating Details
1/7/2016Goldman Sachs Group Inc.Boost Price TargetNeutral$89.00 -> $92.00View Rating Details
11/23/2015VontobelDowngradeHoldView Rating Details
10/28/2015Sanford C. BernsteinLower Price TargetOutperform$102.00View Rating Details
10/28/2015Main First Bank AGDowngradeUnderperformView Rating Details
7/7/2015Oddo SecuritiesInitiated CoverageBuyView Rating Details
6/25/2015HSBCInitiated CoverageBuyView Rating Details
6/22/2015Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details
3/4/2015NatixisUpgradeNeutral -> BuyView Rating Details
1/5/2015Cowen and CompanyUpgradeMarket Perform -> Outperform$95.00 -> $105.00View Rating Details
11/13/2014Kepler Capital MarketsUpgradeHold -> BuyView Rating Details
(Data available from 10/22/2014 forward)


Earnings History for Novartis AG (NYSE:NVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.10$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.21$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
10/28/2014Q3$1.31$1.33$14.51 billion$14.70 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014$1.27$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novartis AG (NYSE:NVS)
Current Year EPS Consensus Estimate: $4.74 EPS
Next Year EPS Consensus Estimate: $5.14 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$1.17$1.18$1.17
Q2 20163$1.12$1.21$1.17
Q3 20162$1.19$1.20$1.20
Q4 20162$1.13$1.24$1.19
(Data provided by Zacks Investment Research)


Current Dividend Information for Novartis AG (NYSE:NVS)
Annual Dividend:$2.30
Dividend Yield:3.04%
Dividend Growth:2.40% (3 Year Average)
Payout Ratio:82.14% (Based on Trailing 12 Months of Earnings)
48.52% (Based on Current Year Consensus EPS Estimate)
44.75% (Based on Next Year Consensus EPS Estimate)

Dividend History for Novartis AG (NYSE:NVS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Novartis AG (NYSE:NVS)
Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 9.77%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Novartis AG (NYSE:NVS)
News IconNovartis AG (ADR) (NVS) Q3 Earnings: What Leerink Expects - Smаrt Stоck Nеws (NYSE:NVS) - October 22 at 10:34 AM
News IconSchulhoff & Co. Inc. invests in Novartis AG (NVS) Shares - DailyQuint (NYSE:NVS) - October 22 at 10:34 AM
News IconThe Key Numbers To Watch From Novartis AG (NYSE:NVS)'s Earnings - The Voice Registrar (NYSE:NVS) - October 22 at 10:34 AM
News IconNgam Advisors LP Raises its position in Novartis AG (NVS) as a favorable investment target. - DailyQuint (NYSE:NVS) - October 22 at 10:34 AM
News IconNovartis AG (NYSE:NVS) from Drug Manufacturers – Major – Todays Top Gains (NYSE:NVS) - October 21 at 6:33 PM logoDo Analysts Expect Negative Growth for Novartis in 3Q16? (NYSE:NVS) - October 21 at 6:33 PM
News IconNovartis AG 3Q 2016 - Forecast (NYSE:NVS) - October 21 at 9:59 AM logoNovartis AG (NYSE:NVS) Invests in Y-Combinator To Develop Lysosomal Storage Disorder Cure (NYSE:NVS) - October 21 at 9:59 AM logoEli Lilly and Co.’s 3Q16: Expectations for Elanco (NYSE:NVS) - October 21 at 9:59 AM logoShould You Buy Novartis (NVS) Ahead of Earnings? (NYSE:NVS) - October 21 at 9:59 AM logoNovartis May Be Too Generic (NYSE:NVS) - October 21 at 9:59 AM
News IconDrug Manufacturers – Major: Novartis AG (NYSE:NVS) Position of the day (NYSE:NVS) - October 20 at 12:18 PM logo15 Biggest Mid-Day Gainers For Wednesday (NYSE:NVS) - October 19 at 1:41 PM
News IconBB&T Corporation, (NYSE:BBT), Novartis, (NYSE:NVS) (NYSE:NVS) - October 19 at 11:38 AM
News IconTop Gainers of the Day: Novartis AG (NYSE:NVS) from Drug Manufacturers – Major (NYSE:NVS) - October 19 at 11:38 AM
News IconHow Novartis AG (NYSE:NVS) trades after earning announcements? - The Independent Republic (NYSE:NVS) - October 18 at 6:25 PM
News IconStocks in Mix Momentum- Novartis AG (NYSE:NVS), Southern Firm ... - Seneca Globe (NYSE:NVS) - October 18 at 11:49 AM
News IconLeading stocks in today’s market: Novartis AG (NYSE:NVS) (NYSE:NVS) - October 17 at 11:40 AM
News IconFormer Novartis AG CAR-T Scientist Jumps to TxCell to Lead CAR-Treg Research Programs (NYSE:NVS) - October 15 at 6:09 PM
News IconStocks in Focus: ENSCO PLC (NYSE:ESV), Novartis AG (ADR)(NYSE:NVS), DISH Network Corp (NASDAQ:DISH) - NYSE Journal (press release) (NYSE:NVS) - October 13 at 6:38 PM
News IconStock Momentum Curbed Pre-Bell, Gapping Down: Novartis AG (NYSE:NVS) - CSZ News (NYSE:NVS) - October 13 at 6:37 PM
News IconAnalysts Roundup at Gainers/Losers- Novartis AG (NYSE:NVS), Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Seneca Globe (NYSE:NVS) - October 13 at 6:37 PM
News IconQuarterly Financial Review of Novartis AG (NYSE:NVS) - The Newburgh Press (NYSE:NVS) - October 13 at 6:37 PM logoNovartis AG (NYSE:NVS) Unveils Positive ASCEND-3, ASCEND-5 Results - Market Exclusive (NYSE:NVS) - October 13 at 6:37 PM logoWorld Health Organization warns that global tuberculosis fight is billions of dollars behind (NYSE:NVS) - October 13 at 10:08 AM
News IconStock Cascading Downward Before Open: Novartis AG (NYSE:NVS) - CSZ News (NYSE:NVS) - October 12 at 11:53 AM logoHow Trial Results Are Moving These 2 Biotech Stocks (NYSE:NVS) - October 10 at 6:04 PM logo3:17 am Novartis reports LEE011 plus letrozole reduced the risk of progression or death by 44% over letrozole alone (NYSE:NVS) - October 10 at 11:16 AM
News IconNovartis AG (NYSE:NVS) Updated Broker Price Targets - The De Soto Edge (NYSE:NVS) - October 9 at 5:52 PM logoEncouraging Results For Ribociclib In Advanced Breast Cancer (NYSE:NVS) - October 9 at 5:52 PM
News IconNovartis AG (NYSE:NVS) Updated Broker Ratings - NewsDen (NYSE:NVS) - October 9 at 10:46 AM
News IconRecently Changed Price Targets On Novartis AG (NYSE:NVS) - NewsDen (NYSE:NVS) - October 7 at 6:15 PM
News IconNovartis AG (NYSE:NVS) lost about -3.9 percent in value since last earnings - The Independent Republic (NYSE:NVS) - October 6 at 6:20 PM logoNovartis AG (NVS) Relocates NITD To California - Insider Monkey (blog) (NYSE:NVS) - October 6 at 6:20 PM
News IconNovartis AG (NVS) Relocates NITD To California (NYSE:NVS) - October 6 at 3:12 PM logoNovartis AG (NYSE:NVS) Relocates NITD To California - Market Exclusive (NYSE:NVS) - October 6 at 12:00 PM
News Icon13F Filing Note: Guyasuta Investment Advisors INC Has Boosted Holding in Novartis Ag Adr (NVS) by $8.14 Million as ... - Chester News (NYSE:NVS) - October 5 at 6:23 PM
News IconBimagrumab (BYM338) drug from Novartis AG (ADR) (NYSE:NVS) Failed a Phase IIb/III study - (NYSE:NVS) - October 5 at 11:45 AM logo[$$] Novartis to shift Singapore research facility (NYSE:NVS) - October 5 at 11:45 AM logoNovartis closes Swiss, Chinese centres in research revamp (NYSE:NVS) - October 5 at 11:45 AM logoNovartis reshapes research, closes some Swiss, Chinese units (NYSE:NVS) - October 5 at 11:45 AM logoNovartis AG (NYSE:NVS) Presents Encouraging Cosentyx Data - Market Exclusive (NYSE:NVS) - October 4 at 6:08 PM logoNovartis AG (NYSE:NVS) Presents Encouraging Cosentyx Data (NYSE:NVS) - October 4 at 11:17 AM logoFriends or Foes: Amgen and Novartis (AMGN, NVS) (NYSE:NVS) - October 3 at 11:04 AM logoNovartis' Cosentyx Shows High, Long-lasting Skin Clearance In Plaque Psoriasis (NYSE:NVS) - October 1 at 5:46 PM
News IconInsider Trading and Upgrades/Downgrades for Novartis AG (NYSE:NVS) - Newburgh Press (NYSE:NVS) - September 30 at 11:46 AM logoSQZ Biotech nabs $16M funding, hires former Novartis exec (NYSE:NVS) - September 30 at 11:46 AM logoWhich Pfizer Products Reported Declining Sales? (NYSE:NVS) - September 30 at 11:46 AM
News IconNeon Therapeutics Taps Former Novartis AG Cancer Vet as New CEO (NYSE:NVS) - September 29 at 6:28 PM logoNovartis AG (NYSE:NVS) EPS Forecast At $1.19? - Stocks Daily (NYSE:NVS) - September 29 at 11:38 AM


Novartis AG (NYSE:NVS) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by Staff